Cyril Amarchand Mangaldas advises on CIRP of Sharon Bio-Medicine

August 02, 2023 10:31 AM CEST | By Businesswire India
 Cyril Amarchand Mangaldas advises on CIRP of Sharon Bio-Medicine
Image source: Businesswire India
Business Wire India
Cyril Amarchand Mangaldas acted as legal counsel for Resolution Professional (RP) and Monitoring Committee of Sharon Bio-Medicine Limited in the corporate insolvency resolution process (CIRP) of Sharon Bio-Medicine Limited (Sharon), a listed Indian pharmaceutical company. During the CIRP under the Insolvency and Bankruptcy Code, 2016 (Code), the Resolution Plan (Resolution Plan) submitted by Innova Captab Limited (‘Successful Resolution Applicant’/ ‘Innova’) and approved the Hon’ble National Company Law Tribunal, Mumbai Bench (NCLT) was successfully implemented, resulting in acquisition of 100% shareholding of Sharon through its subsidiary Univentis Medicare Limited.

The Project & Project Finance, Insolvency & Dispute Resolution Practices of Cyril Amarchand Mangaldas (CAM) advised Mr. Pulkit Gupta, Resolution Professional (RP) during the CIRP till the successful approval of the Resolution Plan, including evaluation and compliance check of the resolution plans submitted by the prospective resolution applicants, and negotiation on the resolution plans.

The CAM Team also advised and represented the RP in various litigations before the Hon’ble NCLT, the Hon’ble National Company Law Appellate Tribunal, New Delhi and the Hon’ble Supreme Court.

The Firm also advised the Monitoring Committee (comprising of the erstwhile RP (as Monitoring Agent), the nominee of the Committee of Creditors (CoC) and the Successful Resolution Applicant) constituted for supervision and implementation of the Resolution Plan. The Resolution Plan was successfully implemented on June 30, 2023, culminating into acquisition of 100% shareholding of the Corporate Debtor by the subsidiary of the Resolution Applicant, i.e., Univentis Medicare Limited.

The transaction team was led by Madhav Kanoria, Partner; with support from Surbhi Pareek, Principal Associate; Srideepa Bhattacharyya, Principal Associate; Anush Mathkar, Principal Associate; Jeta Shree, Senior Associate; Neha Shivhare, Senior Associate; Nayani Agarwal, Associate and Jayesh Karnawat, Associate; who advised the Resolution Professional during the entire corporate insolvency resolution process, including invitation, evaluation and final approval of the resolution plan as well as litigation related aspects of the matter. The team also advised the Committee of Creditors and Monitoring Committee on various aspects of resolution process from time to time.

As part of the transaction, the CIRP was initiated for Sharon pursuant to order of the Hon’ble NCLT, Mumbai, dated April 11, 2017. This is one of the few cases under the Code, in which the earlier successful resolution applicant defaulted in implementing its approved resolution plan leading to inordinate delay in completion of the CIRP. Subsequently, after prolonged litigation and upon the directions of the Supreme Court vide order dated February 28, 2022 and the Hon’ble NCLT vide order dated June 3, 2022, fresh CIRP was initiated in relation to the Corporate Debtor. During the re-initiated CIRP, the Resolution Plan of the Innova was approved by the CoC and the Hon’ble NCLT and was successfully implemented on June 30, 2023. The Resolution Plan resolves a total debt aggregating to INR 9,20,31,69,711 of the Corporate Debtor of which the debt owed to the financial creditors was approximately INR 8,91,77,02,779.
 
Other parties and advisors to the transaction included EY Restructuring LLP (acted as advisor for Mr. Pulkit Gupta -Resolution Professional /Sharon Bio-Medicine Limited).
 
The Resolution Plan was approved by the NCLT, Mumbai on 17th May, 2023 and transaction closed on 30th June, 2023.

To keep reading, please log in to your account, create a free account, or simply fill out the popup form.

Kalkine Media dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium do Kalkine que laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui do Kalkine Media quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui do Kalkine eum fugiat quo voluptas nulla pariatur?

1914 translation by H. Rackham

But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?

1914 translation by H. Rackham

But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles